^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD22-targeted CAR-T immunotherapy

    Related drugs:
    2d
    PLAT-04: A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma (clinicaltrials.gov)
    P1, N=4, Completed, Seattle Children's Hospital | Active, not recruiting --> Completed
    Trial completion
    |
    CD22 (CD22 Molecule)
    6d
    Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Hrain Biotechnology Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Aug 2025 --> May 2027
    Enrollment closed • Trial completion date
    |
    CD22 (CD22 Molecule) • IL15 (Interleukin 15)
    |
    CD22 positive
    |
    anti-CD19/CD22 CAR-T cells
    7d
    CAR-T for R/R B-NHL (clinicaltrials.gov)
    P2, N=168, Completed, The First Affiliated Hospital of Soochow University | Unknown status --> Completed | N=10 --> 168
    Trial completion • Enrollment change
    |
    CD20 (Membrane Spanning 4-Domains A1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CD22 (CD22 Molecule)
    |
    CAR-T CD19/CD20/CD22/CD30
    12d
    Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL (clinicaltrials.gov)
    P2, N=40, Suspended, The First Affiliated Hospital of Soochow University | Not yet recruiting --> Suspended
    Trial suspension
    |
    CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD22/CD19 CAR T
    12d
    OSU-21170: Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=54, Recruiting, Sumithira Vasu | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule)
    |
    cyclophosphamide • fludarabine IV • TriCAR19.20.22 T cells
    13d
    CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL (clinicaltrials.gov)
    P2, N=37, Active, not recruiting, The First Affiliated Hospital of Soochow University | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD22/CD19 CAR T
    21d
    OSU-21170: Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=54, Recruiting, Sumithira Vasu | Trial completion date: Jul 2026 --> Jul 2027
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule)
    |
    cyclophosphamide • fludarabine IV • TriCAR19.20.22 T cells
    27d
    CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma (clinicaltrials.gov)
    P2, N=20, Recruiting, Liping Dou
    New P2 trial
    |
    TP53 (Tumor protein P53) • CD22 (CD22 Molecule) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule)
    |
    TP53 mutation • CD22 positive
    1m
    CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=20, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD22 (CD22 Molecule)
    |
    cyclophosphamide • fludarabine IV
    2ms
    CAR-T Immunotherapy Targeting CD19- ALL (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2023 --> Dec 2029 | Trial primary completion date: Jul 2021 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD38 (CD38 Molecule) • CRLF2 (Cytokine Receptor Like Factor 2) • CD22 (CD22 Molecule) • MME (Membrane Metalloendopeptidase) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR • 4SCAR-T
    2ms
    CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=100, Active, not recruiting, Beijing Tongren Hospital | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2026 --> Apr 2026
    Enrollment closed • Trial primary completion date
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive • CD22 positive